시장보고서

상품코드

1800795

신경퇴행성 질환 치료 시장 보고서 : 적응증별, 약물 유형별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 146 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 신경퇴행성 질환 치료 시장 규모는 2024년 783억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 1,185억 달러에 달할 것으로 예상하며, 2025-2033년 연평균 성장률(CAGR)은 4.48%에 달할 것으로 예측하고 있습니다.

신경퇴행성 질환은 중추신경계(CNS) 또는 말초신경계(PNS) 뉴런의 구조와 기능이 점진적으로 변성되는 뇌질환군을 말합니다. 현재 신체적 또는 정신적 증상을 완화하고 환자의 삶의 질을 향상시키기 위해 여러 가지 약물이 사용되고 있습니다. 또한 연구진은 신경퇴행성 질환을 조기에 발견, 진단하고 진행을 예방하기 위한 분자진단법, 특히 바이오마커와 영상 분광법 개발에 주력하고 있습니다.

과도한 알코올 섭취로 인한 종양과 뇌졸중의 유병률 증가는 노인 인구의 증가와 함께 신경퇴행성 질환의 발병 위험을 높이는 주요 요인 중 하나입니다. 이는 알츠하이머병, 파킨슨병, 헌팅턴병, 근위축성측색경화증 등 신경퇴행성 질환의 조기 진단을 위한 분자진단 기술의 필요성을 더욱 높이고 있습니다. 이와는 별도로, 연구자들은 이러한 질환의 분류를 효과적으로 이해하기 위해 신경병리학적인 방법과 분자생물학적 방법을 결합하고 있습니다. 또한, 다양한 유형의 신경퇴행성 질환에 대한 최소침습(MI) 스크리닝 검사의 개발도 진행 중입니다. 또한, 신경퇴행성 질환의 위험요인에 대한 인식을 높이기 위해 비정부기구(NGO)와 함께 많은 국가의 행정기관이 다양한 건강 교육 캠페인을 지원하고 있습니다. 인프라 개선으로 인한 의료 시설에 대한 접근성 증가와 가처분 소득 증가와 같은 다른 요인들도 향후 몇 년 동안 시장 성장을 촉진할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문

세계 신경퇴행성 질환 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 변화할 것인가?
COVID-19가 세계 신경퇴행성 질환 치료제 시장에 미치는 영향은?
주요 지역 시장은?
적응증별 시장 현황은?
약제 종류별 시장 현황은?
투여 경로별 시장 현황은?
판매 채널별 시장 현황은?
산업 가치사슬의 다양한 단계는 무엇인가?
업계의 주요 촉진요인과 과제는 무엇인가?
세계 신경퇴행성 질환 치료제 시장 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.

Key Market Segmentation:

Breakup by Indication:

Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Huntington's Disease
Others

Breakup by Drug Type:

N-methyl-D-aspartate Receptor Antagonists
Selective Serotonin Reuptake Inhibitors
Dopamine Inhibitors
Others

Breakup by Route of Administration:

Oral
Injectable
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global neurodegenerative disease treatment market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Indication

6.1 Multiple Sclerosis
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Parkinson's Disease
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Alzheimer's Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Spinal Muscular Atrophy (SMA)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Huntington's Disease
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Drug Type

7.1 N-methyl-D-aspartate Receptor Antagonists
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Selective Serotonin Reuptake Inhibitors
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Dopamine Inhibitors
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Biogen
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Boehringer Ingelheim International GmbH
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 F. Hoffmann-La Roche AG
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
- 15.3.4 GlaxoSmithKline Plc
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 SWOT Analysis
- 15.3.5 Merck & Co. Inc.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Novartis AG
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Sanofi S.A
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Teva Pharmaceutical Industries Ltd.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 UCB S.A
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis

신경퇴행성 질환 치료 시장 보고서 : 적응증별, 약물 유형별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

본 보고서에서 다루는 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 신경퇴행성 질환 치료 시장

제6장 시장 내역 : 적응증별

제7장 시장 내역 : 약물 유형별

제8장 시장 내역 : 투여 경로별

제9장 시장 내역 : 유통 채널별

제10장 시장 내역 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도